Pfizer’s outlook disappoints after Viagra loses patent protection and Lyrica faces same fate

Health, Fitness & Food

Pharmaceutical giant Pfizer reported fourth-quarter earnings and revenue on Tuesday that beat Wall Street’s expectations but its guidance for 2019 disappointed investors.

shuffle the company’s senior management team in October, and has been focused on bulking up its pipeline of drugs and therapies, especially in oncology, ahead of impending patent expirations.

Shares of Pfizer have fallen more than 9 percent since the beginning of this year. The stock has increased more than 1 percent over the past 12 months.

Advertisements

Products You May Like

Articles You May Like

What can cause itchy lower legs?
What to know about bone marrow transplants
Retinal imaging shows promise in early detection of Alzheimer’s
Lymphoma rash: What to know
Illiteracy may triple dementia risk

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.